oplunofusp

antiviral; a sialidase fusion protein (consisting of sialidase catalytic domain derived from Actinomyces viscosus fused with respiratory epithelium-anchoring domain) that protects mice from lethal avian influenza H5N1 virus infection

Also Known As:

Networked: 32 relevant articles (4 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fang, Fang: 11 articles (10/2011 - 04/2006)
2.	Moss, Ronald B: 7 articles (05/2016 - 11/2009)
3.	Aschenbrenner, Laura M: 5 articles (08/2011 - 04/2006)
4.	Hedlund, Maria: 5 articles (08/2011 - 11/2009)
5.	Larson, Jeffrey L: 5 articles (08/2011 - 11/2009)
6.	Gubareva, Larisa V: 4 articles (08/2014 - 04/2006)
7.	Nicholls, John M: 4 articles (06/2013 - 09/2009)
8.	Hawley, Stephen: 3 articles (01/2021 - 11/2007)
9.	Moss, R B: 3 articles (01/2016 - 02/2013)
10.	Mishin, Vasiliy P: 3 articles (08/2014 - 04/2006)

Related Diseases

1.	Human Influenza (Influenza) 11/01/2015 - "Treatment of influenza for three days with DAS181 reduced viral shedding. " 08/01/2014 - "The results warrant further investigation of DAS181 for influenza treatment. " 11/06/2009 - "DAS181 treatment also protected mice from pandemic influenza A(H1N1)-induced pathogenesis. " 11/06/2009 - "DAS181 efficiently inhibited viral replication in each of these models and against all tested pandemic influenza A(H1N1) strains. " 11/06/2009 - "The activity of DAS181 against several pandemic influenza A(H1N1) virus isolates was examined in MDCK cells, differentiated primary human respiratory tract culture, ex-vivo human bronchi tissue and mice. "
2.	COVID-19 10/01/2020 - "Efficacy and safety, including pharmacokinetics and viral studies of DAS181 in severe, hypoxic coronavirus disease 2019, should be examined by a double-blind, randomized controlled study." 10/01/2020 - "The objective of this study (NCT04324489) is to investigate the safety and effects of nebulized DAS181 on hypoxic coronavirus disease 2019 patients. " 10/01/2020 - "Three male coronavirus disease 2019 hypoxic patients with bilateral lung involvement completed DAS181 treatment for 10 days. " 10/01/2020 - "Resolution of Coronavirus Disease 2019 Infection and Pulmonary Pathology With Nebulized DAS181: A Pilot Study." 01/01/2021 - "We describe the successful treatment of a 10-month-old female with respiratory distress secondary to Coronavirus disease 2019 (COVID-19) with the nebulized investigational drug, DAS181. "
3.	Anemia 08/01/2011 - "A laboratory abnormality observed in the 28-day toxicology study was mild and transient anemia in male rats at the 3.00 mg/kg dose, which is an expected outcome of enhanced clearance of desialylated red blood cells resulting from systemic exposure with DAS181. "
4.	Influenza in Birds (Avian Flu) 11/15/2007 - "Here, we use a mouse model to evaluate the efficacy of DAS181 treatment against a highly pathogenic avian influenza H5N1 virus. " 09/01/2009 - "DAS181 treatment also effectively protects human lung tissue and pneumocytes against the highly pathogenic avian influenza virus H5N1 (A/Vietnam/3046/2004). " 09/01/2009 - "DAS181 and its analogues have previously been shown to be potently active against multiple strains of seasonal and avian influenza virus strains in several experimental models, including cell lines, mice, and ferrets. " 04/01/2006 - "We demonstrate that a sialidase fusion construct, DAS181, effectively cleaves sialic acid receptors used by both human and avian influenza viruses. " 11/06/2009 - "DAS181 (Fludase), a sialidase fusion protein, has been shown to have inhibitory activity against a large number of seasonal influenza strains and a highly pathogenic avian influenza (HPAI) strain (H5N1). "
5.	Infections 05/01/2016 - "We report the clinical manifestations and outcomes of 16 HSCT recipients who received DAS181 daily for the treatment of PIV infection through a compassionate-use protocol or a single-arm clinical trial. " 12/01/2015 - "DAS181 blocked infection of human metapneumovirus strains A2, B1, and B2 at low concentrations. " 02/01/2013 - "DAS181 should be systematically evaluated for treatment of PIV infection in transplant recipients." 08/01/2012 - "Clinical potential of DAS181 for treatment of parainfluenza-3 infections in transplant recipients." 10/01/2011 - "DAS181 should be systematically evaluated for severe PIV infection."

Related Drugs and Biologics

1.	Antiviral Agents (Antivirals)
2.	Neuraminidase (Sialidase)
3.	Proteins (Proteins, Gene)
4.	Oseltamivir (Tamiflu)
5.	Nucleoproteins
6.	brincidofovir
7.	baloxavir
8.	N-Acetylneuraminic Acid (Sialic Acid)
9.	Investigational Drugs
10.	Oxygen (Dioxygen)

Related Therapies and Procedures

1.	Therapeutics
2.	Artificial Respiration (Mechanical Ventilation)
3.	Stem Cell Transplantation